Rockwell Medical (NASDAQ:RMTI) was upgraded by equities researchers at ValuEngine from a “sell” rating to a “hold” rating in a research note issued to investors on Wednesday.
RMTI has been the subject of several other reports. Zacks Investment Research downgraded Rockwell Medical from a “hold” rating to a “sell” rating in a research note on Wednesday, June 6th. BidaskClub raised shares of Rockwell Medical from a “sell” rating to a “hold” rating in a research report on Tuesday, March 13th.
Shares of RMTI traded down $0.74 during trading hours on Wednesday, hitting $4.52. The stock had a trading volume of 1,053,563 shares, compared to its average volume of 248,285. The company has a market cap of $272.30 million, a PE ratio of -8.86 and a beta of 2.19. Rockwell Medical has a 1-year low of $4.45 and a 1-year high of $8.70.
Rockwell Medical (NASDAQ:RMTI) last issued its earnings results on Thursday, May 10th. The company reported ($0.13) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.14) by $0.01. The company had revenue of $14.95 million during the quarter. Rockwell Medical had a negative return on equity of 76.49% and a negative net margin of 48.06%. equities research analysts predict that Rockwell Medical will post -0.39 earnings per share for the current fiscal year.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Schwab Charles Investment Management Inc. lifted its position in Rockwell Medical by 21.9% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 95,900 shares of the company’s stock valued at $500,000 after acquiring an additional 17,200 shares in the last quarter. MetLife Investment Advisors LLC bought a new position in Rockwell Medical in the 4th quarter valued at about $110,000. Millennium Management LLC bought a new position in Rockwell Medical in the 4th quarter valued at about $217,000. Goldman Sachs Group Inc. lifted its position in Rockwell Medical by 117.3% in the 4th quarter. Goldman Sachs Group Inc. now owns 27,139 shares of the company’s stock valued at $158,000 after acquiring an additional 14,648 shares in the last quarter. Finally, Deutsche Bank AG lifted its position in Rockwell Medical by 107.7% in the 4th quarter. Deutsche Bank AG now owns 121,202 shares of the company’s stock valued at $704,000 after acquiring an additional 62,842 shares in the last quarter. 21.21% of the stock is currently owned by institutional investors and hedge funds.
Rockwell Medical Company Profile
Rockwell Medical, Inc operates as an integrated biopharmaceutical company targeting end-stage renal and chronic kidney diseases in the United States and internationally. The company's lead drug includes Triferic, an iron maintenance therapy that replaces the iron lost by patients during hemodialysis treatment.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Rockwell Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical and related companies with MarketBeat.com's FREE daily email newsletter.